CN1321669A - 一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸 - Google Patents

一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸 Download PDF

Info

Publication number: CN1321669A
Authority: CN; China
Prior art keywords: polypeptide; polynucleotide; sequence; myb protein; human myb
Prior art date: 2000-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 00115541

Other languages

English (en)

Chinese (zh)

Inventor

毛裕民

谢毅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Biowindow Gene Development Inc

Original Assignee

Shanghai Biowindow Gene Development Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-29

Filing date

2000-04-29

Publication date

2001-11-14

2000-04-29 Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc

2000-04-29 Priority to CN 00115541 priority Critical patent/CN1321669A/zh

2001-04-28 Priority to AU67278/01A priority patent/AU6727801A/en

2001-04-28 Priority to PCT/CN2001/000627 priority patent/WO2001083741A1/fr

2001-11-14 Publication of CN1321669A publication Critical patent/CN1321669A/zh

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 116
102000040430 polynucleotide Human genes 0.000 title claims abstract description 114
108091033319 polynucleotide Proteins 0.000 title claims abstract description 114
239000002157 polynucleotide Substances 0.000 title claims abstract description 114
229920001184 polypeptide Polymers 0.000 title claims abstract description 110
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 109
101710147844 Myb protein Proteins 0.000 title claims abstract description 11
101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 claims abstract description 119
102000056573 human MYB Human genes 0.000 claims abstract description 119
238000000034 method Methods 0.000 claims abstract description 85
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
201000010099 disease Diseases 0.000 claims abstract description 27
239000005557 antagonist Substances 0.000 claims abstract description 17
201000011510 cancer Diseases 0.000 claims abstract description 11
208000026278 immune system disease Diseases 0.000 claims abstract description 4
208000031886 HIV Infections Diseases 0.000 claims abstract description 3
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 3
206010061218 Inflammation Diseases 0.000 claims abstract description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 3
230000004054 inflammatory process Effects 0.000 claims abstract description 3
239000000523 sample Substances 0.000 claims description 72
108090000623 proteins and genes Proteins 0.000 claims description 67
230000014509 gene expression Effects 0.000 claims description 54
238000009396 hybridization Methods 0.000 claims description 37
239000002773 nucleotide Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 18
108020004707 nucleic acids Proteins 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 15
239000013604 expression vector Substances 0.000 claims description 13
239000013598 vector Substances 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 11
239000013612 plasmid Substances 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 10
239000000556 agonist Substances 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 6
230000003321 amplification Effects 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000000692 anti-sense effect Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
238000002493 microarray Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000008485 antagonism Effects 0.000 claims description 2
238000013459 approach Methods 0.000 claims description 2
208000022602 disease susceptibility Diseases 0.000 claims description 2
238000001727 in vivo Methods 0.000 claims description 2
238000004088 simulation Methods 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
238000004519 manufacturing process Methods 0.000 abstract description 12
230000001225 therapeutic effect Effects 0.000 abstract description 2
238000012270 DNA recombination Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 70
108020004414 DNA Proteins 0.000 description 45
150000001413 amino acids Chemical group 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 31
238000005516 engineering process Methods 0.000 description 29
102000004169 proteins and genes Human genes 0.000 description 23
235000018102 proteins Nutrition 0.000 description 22
210000001519 tissue Anatomy 0.000 description 22
229940024606 amino acid Drugs 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
239000000047 product Substances 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
206010028980 Neoplasm Diseases 0.000 description 18
230000008859 change Effects 0.000 description 16
108091034117 Oligonucleotide Proteins 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
101150078498 MYB gene Proteins 0.000 description 10
230000006870 function Effects 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
230000008034 disappearance Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000000926 separation method Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
108700021654 myb Genes Proteins 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
238000012216 screening Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000005406 washing Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 7
108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000008521 reorganization Effects 0.000 description 7
210000001541 thymus gland Anatomy 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000008569 process Effects 0.000 description 6
238000001228 spectrum Methods 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
206010025323 Lymphomas Diseases 0.000 description 5
230000008827 biological function Effects 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
238000000018 DNA microarray Methods 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
229910052785 arsenic Inorganic materials 0.000 description 4
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
-1 liver Chemical compound 0.000 description 4
201000005202 lung cancer Diseases 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
206010010356 Congenital anomaly Diseases 0.000 description 3
CUXIOFHFFXNUGG-HTFCKZLJSA-N Cys-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CS)N CUXIOFHFFXNUGG-HTFCKZLJSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
108020005091 Replication Origin Proteins 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000013016 damping Methods 0.000 description 3
230000034994 death Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
206010016629 fibroma Diseases 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
210000004754 hybrid cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000002429 large intestine Anatomy 0.000 description 3
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 3
238000013507 mapping Methods 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
238000000746 purification Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
230000033764 rhythmic process Effects 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
229960004249 sodium acetate Drugs 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
208000003200 Adenoma Diseases 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
208000032170 Congenital Abnormalities Diseases 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
208000006168 Ewing Sarcoma Diseases 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102100034711 Myb-related protein A Human genes 0.000 description 2
101710115158 Myb-related protein A Proteins 0.000 description 2
102100034670 Myb-related protein B Human genes 0.000 description 2
101710115153 Myb-related protein B Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
208000007913 Pituitary Neoplasms Diseases 0.000 description 2
201000005746 Pituitary adenoma Diseases 0.000 description 2
206010061538 Pituitary tumour benign Diseases 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000008175 fetal development Effects 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000002969 morbid Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
238000012856 packing Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
208000021310 pituitary gland adenoma Diseases 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
230000017105 transposition Effects 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
AFMZNQYNOSEBLP-YGOYTEALSA-N 5-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-prop-2-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@]1(CC#C)O[C@H](CO)[C@@H](O)C1 AFMZNQYNOSEBLP-YGOYTEALSA-N 0.000 description 1
FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
QQACQIHVWCVBBR-GVARAGBVSA-N Ala-Ile-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QQACQIHVWCVBBR-GVARAGBVSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
NAARDJBSSPUGCF-FXQIFTODSA-N Arg-Cys-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N NAARDJBSSPUGCF-FXQIFTODSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010008723 Chondrodystrophy Diseases 0.000 description 1
201000005262 Chondroma Diseases 0.000 description 1
206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010010506 Congenital hydrocephalus Diseases 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
PKNIZMPLMSKROD-BIIVOSGPSA-N Cys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N PKNIZMPLMSKROD-BIIVOSGPSA-N 0.000 description 1
JEKIARHEWURQRJ-BZSNNMDCSA-N Cys-Phe-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CS)N JEKIARHEWURQRJ-BZSNNMDCSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
208000002699 Digestive System Neoplasms Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
201000005231 Epithelioid sarcoma Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
206010061183 Genitourinary tract neoplasm Diseases 0.000 description 1
208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018381 Glomus tumour Diseases 0.000 description 1
206010018404 Glucagonoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
MFQVZYSPCIZFMR-MGHWNKPDSA-N His-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N MFQVZYSPCIZFMR-MGHWNKPDSA-N 0.000 description 1
JMSONHOUHFDOJH-GUBZILKMSA-N His-Ser-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 JMSONHOUHFDOJH-GUBZILKMSA-N 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
RFMDODRWJZHZCR-BJDJZHNGSA-N Ile-Lys-Cys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(O)=O RFMDODRWJZHZCR-BJDJZHNGSA-N 0.000 description 1
VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010050638 Langer-Giedion syndrome Diseases 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
GZAUZBUKDXYPEH-CIUDSAMLSA-N Leu-Cys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N GZAUZBUKDXYPEH-CIUDSAMLSA-N 0.000 description 1
GOFJOGXGMPHOGL-DCAQKATOSA-N Leu-Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C GOFJOGXGMPHOGL-DCAQKATOSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
206010025219 Lymphangioma Diseases 0.000 description 1
208000004138 Lymphangiomyoma Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
JYXBNQOKPRQNQS-YTFOTSKYSA-N Lys-Ile-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JYXBNQOKPRQNQS-YTFOTSKYSA-N 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 1
XDGFFEZAZHRZFR-RHYQMDGZSA-N Met-Leu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDGFFEZAZHRZFR-RHYQMDGZSA-N 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000007182 Myelolipoma Diseases 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010054076 Oncogene Proteins v-myb Proteins 0.000 description 1
208000001715 Osteoblastoma Diseases 0.000 description 1
208000004286 Osteochondrodysplasias Diseases 0.000 description 1
208000000035 Osteochondroma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010033964 Parathyroid tumour benign Diseases 0.000 description 1
JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035603 Pleural mesothelioma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
208000034541 Rare lymphatic malformation Diseases 0.000 description 1
208000005678 Rhabdomyoma Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
HEUVHBXOVZONPU-BJDJZHNGSA-N Ser-Leu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HEUVHBXOVZONPU-BJDJZHNGSA-N 0.000 description 1
PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010068771 Soft tissue neoplasm Diseases 0.000 description 1
201000010829 Spina bifida Diseases 0.000 description 1
208000006097 Spinal Dysraphism Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
UGFSAPWZBROURT-IXOXFDKPSA-N Thr-Phe-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N)O UGFSAPWZBROURT-IXOXFDKPSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000000728 Thymus Neoplasms Diseases 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
208000024212 Tracheal Neoplasms Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
208000035378 Trichorhinophalangeal syndrome type 2 Diseases 0.000 description 1
PEYSVKMXSLPQRU-FJHTZYQYSA-N Trp-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O PEYSVKMXSLPQRU-FJHTZYQYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
206010049644 Williams syndrome Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
208000026565 adrenal gland myelolipoma Diseases 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
206010002320 anencephaly Diseases 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
201000003433 benign pleural mesothelioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000011143 bone giant cell tumor Diseases 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
229940090045 cartridge Drugs 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000012295 chemical reaction liquid Substances 0.000 description 1
201000005217 chondroblastoma Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
201000000292 clear cell sarcoma Diseases 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
201000009458 epididymis cancer Diseases 0.000 description 1
208000006791 epispadias Diseases 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
208000028991 esophageal small cell neuroendocrine carcinoma Diseases 0.000 description 1
201000002726 esophagus leiomyosarcoma Diseases 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
206010049444 fibromatosis Diseases 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000005357 flat glass Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
201000007487 gallbladder carcinoma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010049041 glutamylalanine Proteins 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036449 good health Effects 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
201000000284 histiocytoma Diseases 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000003906 hydrocephalus Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
201000009370 intramuscular hemangioma Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
201000000062 kidney sarcoma Diseases 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
208000035853 malformation syndrome Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
208000004197 mesenchymoma Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
210000001167 myeloblast Anatomy 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
208000025189 neoplasm of testis Diseases 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
201000011682 nervous system cancer Diseases 0.000 description 1
206010061311 nervous system neoplasm Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
208000029974 neurofibrosarcoma Diseases 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
208000003388 osteoid osteoma Diseases 0.000 description 1
201000003686 parathyroid adenoma Diseases 0.000 description 1
201000003913 parathyroid carcinoma Diseases 0.000 description 1
208000014643 parathyroid gland adenoma Diseases 0.000 description 1
208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
208000030761 polycystic kidney disease Diseases 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004491 retinal development Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
206010062920 spondyloepiphyseal dysplasia Diseases 0.000 description 1
201000002962 spondyloepiphyseal dysplasia with congenital joint dislocations Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000005222 synovial tissue Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
201000008321 testicular Leydig cell tumor Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
208000024363 trachea neoplasm Diseases 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
201000006532 trichorhinophalangeal syndrome type II Diseases 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
208000025444 tumor of salivary gland Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN 00115541 2000-04-29 2000-04-29 一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸 Pending CN1321669A (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN 00115541 CN1321669A (zh)	2000-04-29	2000-04-29	一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸
AU67278/01A AU6727801A (en)	2000-04-29	2001-04-28	A novel polypeptide, a myb human protein 10 and the polynucleotide encoding the polypeptide
PCT/CN2001/000627 WO2001083741A1 (fr)	2000-04-29	2001-04-28	Nouveau polypeptide, proteine myb humaine 10, et polynucleotide codant pour ce polypeptide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN 00115541 CN1321669A (zh)	2000-04-29	2000-04-29	一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸

Publications (1)

Publication Number	Publication Date
CN1321669A true CN1321669A (zh)	2001-11-14

Family

ID=4584987

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 00115541 Pending CN1321669A (zh)	2000-04-29	2000-04-29	一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸

Country Status (3)

Country	Link
CN (1)	CN1321669A (fr)
AU (1)	AU6727801A (fr)
WO (1)	WO2001083741A1 (fr)

2000
- 2000-04-29 CN CN 00115541 patent/CN1321669A/zh active Pending
2001
- 2001-04-28 WO PCT/CN2001/000627 patent/WO2001083741A1/fr not_active Ceased
- 2001-04-28 AU AU67278/01A patent/AU6727801A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001083741A1 (fr)	2001-11-08
AU6727801A (en)	2001-11-12

Publication	Publication Date	Title
CN1325854A (zh)	2001-12-12	一种新的多肽——高迁移率组分蛋白10和编码这种多肽的多核苷酸
CN1331319A (zh)	2002-01-16	一种新的多肽——sr蛋白特异性丝氨酸激酶212.98和编码这种多肽的多核苷酸
CN1321669A (zh)	2001-11-14	一种新的多肽——人myb蛋白10和编码这种多肽的多核苷酸
CN1328029A (zh)	2001-12-26	一种新的多肽——人tre致癌基因蛋白10.56和编码这种多肽的多核苷酸
CN1321664A (zh)	2001-11-14	一种新的多肽——人Pax蛋白23和编码这种多肽的多核苷酸
CN1329091A (zh)	2002-01-02	一种新的多肽——人原肌球结合蛋白9和编码这种多肽的多核苷酸
CN1315438A (zh)	2001-10-03	一种新的多肽——人碳代谢副产物阻遏蛋白相关蛋白16和编码这种多肽的多核苷酸
CN1326949A (zh)	2001-12-19	一种新的多肽——人视锥蛋白类似蛋白17.27和编码这种多肽的多核苷酸
CN1324862A (zh)	2001-12-05	一种新的多肽——人ccr4相关蛋白9.5和编码这种多肽的多核苷酸
CN1324854A (zh)	2001-12-05	一种新的多肽——人剪切蛋白10.56和编码这种多肽的多核苷酸
CN1322755A (zh)	2001-11-21	一种新的多肽——人Pax蛋白9和编码这种多肽的多核苷酸
CN1324837A (zh)	2001-12-05	一种新的多肽——人自然死亡细胞增强因子b13.64和编码这种多肽的多核苷酸
CN1345826A (zh)	2002-04-24	一种新的多肽——人视醛结合蛋白76.34和编码这种多肽的多核苷酸
CN1321657A (zh)	2001-11-14	一种新的多肽——人myb蛋白14和编码这种多肽的多核苷酸
CN1321686A (zh)	2001-11-14	一种新的多肽——人myb蛋白41和编码这种多肽的多核苷酸
CN1313334A (zh)	2001-09-19	一种新的多肽——人肉瘤蛋白67和编码这种多肽的多核苷酸
CN1363592A (zh)	2002-08-14	一种新的多肽——人肉瘤蛋白8.91和编码这种多肽的多核苷酸
CN1277970A (zh)	2000-12-27	一种新的多肽——人肉瘤蛋白20和编码这种多肽的多核苷酸
CN1323814A (zh)	2001-11-28	一种新的多肽——人ccr4相关蛋白9和编码这种多肽的多核苷酸
CN1325886A (zh)	2001-12-12	一种新的多肽——人Myb蛋白32和编码这种多肽的多核苷酸
CN1300754A (zh)	2001-06-27	一种新的多肽－myb蛋白9和编码这种多肽的多核苷酸
CN1343710A (zh)	2002-04-10	一种新的多肽——人锌指蛋白9.79和编码这种多肽的多核苷酸
CN1312273A (zh)	2001-09-12	一种新的多肽——人脂蛋白前提蛋白信号肽10和编码这种多肽的多核苷酸
CN1343695A (zh)	2002-04-10	一种新的多肽——人含配对盒结构域的蛋白15.95和编码这种多肽的多核苷酸
CN1333285A (zh)	2002-01-30	一种新的多肽——人剪切因子14.08和编码这种多肽的多核苷酸

Legal Events

Date	Code	Title
2001-11-14	C06	Publication
2001-11-14	PB01	Publication
2003-12-31	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2003-12-31	WD01	Invention patent application deemed withdrawn after publication